PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Notes Phase 1 data for LYT-100 shows treatment was well-tolerated when given twice-daily over multiple ascending doses with no maximum tolerated dose observed. LYT-100 is currently being evaluated in two Phase 2 trials in patients with Long Covid respiratory complications or breast cancer-related, upper limb secondary lymphedema, and planning is underway to potentially evaluate LYT-100 in IPF.
Head of Innovation at PureTech Michael Chen says: "These data further support the favourable tolerability profile of LYT-100 and have helped inform both our ongoing Phase 2 trials as well as potential future trials in additional indications, including idiopathic pulmonary fibrosis.
"LYT-100 is a deuterated form of pirfenidone, which retains the beneficial pharmacology of pirfenidone and also appears to have a favorable tolerability profile based on the preclinical and clinical data generated thus far. We believe this molecule has the potential to overcome the GI adverse events associated with the current standards of care and become the frontline treatment for patients with interstitial lung disease."
Current stock price: 333.50 pence
Year-to-date change: down 17%
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
PureTech (PRTC)